Hypomethylating agent

From Wikipedia, the free encyclopedia
Jump to: navigation, search

A hypomethylating agent is a drug that inhibits DNA methylation.

The term "demethylating agent" is also used.[1]

They are undergoing investigation for use in the treatment of tumors.[2]

Examples include:

See also[edit]


  1. ^ Garcia-Manero G (November 2008). "Demethylating agents in myeloid malignancies". Curr Opin Oncol 20 (6): 705–10. doi:10.1097/CCO.0b013e328313699c. PMID 18841054. 
  2. ^ Hambach L, Ling KW, Pool J et al. (December 2008). "Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy". Blood 113 (12): 2715–22. doi:10.1182/blood-2008-05-158956. PMID 19096014. 
  3. ^ Aribi A, Borthakur G, Ravandi F et al. (February 2007). "Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia". Cancer 109 (4): 713–7. doi:10.1002/cncr.22457. PMID 17219444. 
  4. ^ De Padua Silva L, de Lima M, Kantarjian H et al. (January 2009). "Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome". Bone Marrow Transplant. 43 (11): 839–43. doi:10.1038/bmt.2008.400. PMID 19151791. 
  5. ^ Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S (September 2008). "A pilot pharmacokinetic study of oral azacitidine". Leukemia 22 (9): 1680–4. doi:10.1038/leu.2008.145. PMID 18548103.